Pseudallescheria boydii infections treated with ketoconazole. Clinical evaluations of seven patients and in vitro susceptibility results.
Seven patients infected with Pseudallescheria boydii were treated with oral ketoconazole, 200 to 600 mg/day for one to 13 months. Five patients had pulmonary infections; two had skeletal infections. Improvement of pretreatment abnormalities occurred in five patients, one of whom had concurrent arthrodesis of his infected knee. The other two patients were subsequently healed by surgical resection of their pulmonary lesions. Ketoconazole appeared less active than miconazole against 22 clinical isolates of P boydii when tested by two in vitro methods. We conclude that ketoconazole is effective treatment for some patients infected with P boydii, although this may not be predicted by current in vitro susceptibility tests. Further experience is needed to establish the optimal use of ketoconazole with respect to its dosage, duration of administration and concurrent surgical resection.
D000368:Aged; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007654:Ketoconazole / Q000494:pharmacology / Q000627:therapeutic use*; D008172:Lung Diseases, Fungal / Q000188:drug therapy* / Q000601:surgery; D008297:Male; D008825:Miconazole / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D008271:Mycetoma / Q000188:drug therapy* / Q000601:surgery; D010019:Osteomyelitis / Q000188:drug therapy / Q000209:etiology
D008825:Miconazole; D007654:Ketoconazole